Hologic (HOLX) : Lateef Investment Management reduced its stake in Hologic by 7.86% during the most recent quarter end. The investment management company now holds a total of 5,384,915 shares of Hologic which is valued at $208,288,512 after selling 459,432 shares in Hologic , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Hologic makes up approximately 6.06% of Lateef Investment Management’s portfolio.
Other Hedge Funds, Including , Partner Fund Management reduced its stake in HOLX by selling 962,240 shares or 67.92% in the most recent quarter. The Hedge Fund company now holds 454,488 shares of HOLX which is valued at $17,579,596. Hologic makes up approx 0.60% of Partner Fund Management’s portfolio.Mizuho Asset Managementltd. boosted its stake in HOLX in the latest quarter, The investment management firm added 1,568 additional shares and now holds a total of 3,313 shares of Hologic which is valued at $128,147. Hologic makes up approx 0.02% of Mizuho Asset Managementltd.’s portfolio. Secor Capital Advisors Lp sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 61,412 shares of HOLX which is valued $2,385,856. Ipswich Investment Management sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 520 shares of HOLX which is valued $20,280.Signaturefd boosted its stake in HOLX in the latest quarter, The investment management firm added 421 additional shares and now holds a total of 442 shares of Hologic which is valued at $17,013.
Hologic opened for trading at $38.39 and hit $38.58 on the upside on Thursday, eventually ending the session at $38.46, with a gain of 0.10% or 0.04 points. The heightened volatility saw the trading volume jump to 16,99,124 shares. Company has a market cap of $10,670 M.
On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.
Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .
Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Companys business units are focused on diagnostics breast health GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.